IDweek2023 | A Comprehensive Analysis of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) versus Dolutegravir/Lamivudine (DTG/3TC) in HIV Treatment
IDweek2023 A Comprehensive Analysis of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) versus Dolutegravir/Lamivudine (DTG/3TC) in HIV Treatment
In the relentless battle against HIV, the advent of antiretroviral therapy (ART) has marked a significant turning point. The development and introduction of drug regimens have revolutionized HIV treatment, transforming HIV from a fatal illness into a manageable chronic condition. However, the dynamic nature of the virus and its ability to develop resistance to drugs necessitates continuous research into new treatment strategies.